Adi Hoess, Affimed CEO

AACR22: Af­fimed's NK cell ther­a­py pro­duces more pa­tient re­spons­es — and more dura­bil­i­ty ques­tions

NEW OR­LEANS — One year af­ter sur­pris­ing the AACR crowd with sol­id ini­tial NK cell da­ta, Af­fimed is back with an­oth­er cut Sun­day.

And while the Ger­man biotech tacked on an­oth­er three com­plete re­spons­es since a No­vem­ber up­date, ques­tions around dura­bil­i­ty will po­ten­tial­ly start to loom larg­er. One pa­tient with a pre­vi­ous­ly record­ed CR has since pro­gressed 7.9 months af­ter treat­ment, Af­fimed said Sun­day, and four with par­tial re­spons­es al­so saw their can­cers wors­en af­ter rough­ly three months each. On the flip side, Af­fimed al­so saw two pa­tients main­tain their com­plete re­spons­es be­yond the 10-month mark.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.